Article
Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
HIV medicine - 1 May 2021
Baxter J D, Dunn D, Tostevin A, Marvig R L, Bennedbaek M, Cozzi-Lepri A, Sharma S, Kozal M J, Gompels M, Pinto A N, Lundgren J
Abstract excerpt
OBJECTIVES: The aim of this analysis was to characterize transmitted drug resistance (TDR) in Strategic Timing of Antiretroviral Treatment (START) study participants by next-generation sequencing (NGS), a sensitive assay capable of detecting low-frequency variants. METHODS: Stored plasma from participants with entry HIV RNA > 1000 copies/mL were analysed by NGS (Illumina MiSeq). TDR was based on the WHO 2009...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.